How Helical built an in-silico lab for translational target discovery and validated it across 11+ indications and four therapeutic areas, including work independently run and assessed by pharmaceutical partners.
Helical raises $10M seed, led by redalpine, to scale the virtual AI lab that turns biological foundation models into reproducible discovery systems.
Helical and Tanabe Pharma America are running in-silico perturbation experiments across ALS and related neurodegenerative diseases.
Helical and Pfizer are putting the Virtual Lab to work, discovering predictive blood-based safety biomarkers in production for biomarker discovery.
For in-depth community discussions about the latest Bio foundation models and how to use them.
Only for updates about new foundation models and the
latest scientific breakthrough in AI for Bio.
